B
Bei Zhang
Researcher at University of Pittsburgh
Publications - 4
Citations - 53
Bei Zhang is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 11 citations.
Papers
More filters
Journal ArticleDOI
Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer.
Jingjing Sun,Zhuoya Wan,Jieni Xu,Zhangyi Luo,Pengfei Ren,Bei Zhang,Dingwei Diao,Yixian Huang,Song Li +8 more
TL;DR: In this article, two types of polydopamine (dp)-coated nanoparticles (NPs) (N/PGEM/dp-5 and N/PGE/dp)-16) were used for effective immunochemo-photothermal therapy (PTT) to inhibit both primary tumor and distal metastatic tumor.
Journal ArticleDOI
Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages
Pearl Moharil,Tấn Đỗ,Zhuoya Wan,Apurva Pardeshi,Jiang Li,Haozhe Huang,Zhangyi Luo,Sanjay Rathod,Ziqian Zhang,Yuang Chen,Bei Zhang,Christian A. Fernandez,Jingjing Sun,Song Li +13 more
TL;DR: Interestingly, in vivo, systemic delivery of FA-PGEM/DOX led to enhanced accumulation of the NPs in tumor and drastic reduction of tumor growth in a murine 4T1.2 breast cancer model, suggesting targeting of TAM may also contribute to the improved in vivo targeted delivery and therapeutic efficacy.
Journal ArticleDOI
Metformin-conjugated micellar system with intratumoral pH responsive de-shielding for co-delivery of doxorubicin and nucleic acid
Yanhua Liu,Jingjing Sun,Yixian Huang,Yichao Chen,Jiang Li,Lei Liang,Jieni Xu,Zhuoya Wan,Bei Zhang,Zuojun Li,Song Li +10 more
TL;DR: In this paper, a polymetformin-based polymeric micellar carrier was developed for tumor-targeted co-delivery of DOX and nucleic acids (NA), based on a structure designed to lose the PEG shell in response to the acidic extracellular tumor environment.
Journal ArticleDOI
Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier
Zhuoya Wan,Haozhe Huang,Raymond E. West III,Jinghui Zhang,Bei Zhang,Xinran Cai,Ziqian Zhang,Zhangyi Luo,Yuang Tsong Chen,Yue Zhang,Wen Xie,Da Yang,Thomas D. Nolin,Junmei Wang,Song Li,Jingjing Sun +15 more
TL;DR: In this article , a "one stone hits two birds" nanoparticle-based strategy was designed to simultaneously activate STING innate immune response while eliminating STING-associated immune resistance for the treatment of pancreatic ductal adenocarcinoma (PDAC).